Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cardio metabolic
Show results for
Products
Services
Applications

Companies

News

Refine by
Date

  • Older

Cardio Metabolic Articles & Analysis: Older

8 news found

Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development

Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development

Her leadership and extensive drug development experience at Amgen, Merck, and Greenfire Bio aligns with the company’s drug discovery interests across multiple therapeutic areas, including cardio-metabolic, pulmonary, inflammatory ophthalmology, renal and fibrotic diseases. ...

ByJuvena Therapeutics, inc.


Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), ...

ByAlnylam Pharmaceuticals, Inc.


INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

INOVIQ carving itself healthy share of multi-billion dollar medical diagnostics market

“Our current focus is cancer, but there’s other diseases where our EXO-NET technology applies, including neurodegenerative diseases, inflammatory diseases and cardio-metabolic conditions,” Dr Hinch said. “Our SubB2M technology can be applied to detect and monitor other cancers in addition to breast and ovarian cancers, such as colorectal, ...

ByINOVIQ Ltd


TreeFrog Therapeutics launches a $100,000 research grant in regenerative medicine

TreeFrog Therapeutics launches a $100,000 research grant in regenerative medicine

Bringing together over 80 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the field of neurodegeneration, cardio-metabolic disorders, and immuno-oncology. In 2022, the company is opening technological hubs in Boston, USA, and Kobe, Japan, to ...

ByTreefrog Therapeutics


TreeFrog Therapeutics expands Board with new independent members from the cell therapy industry

TreeFrog Therapeutics expands Board with new independent members from the cell therapy industry

Bringing together over 80 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the field of neurodegeneration, cardio-metabolic disorders and immuno-oncology. The company is currently opening technological hubs in Boston, USA, and Kobe, Japan, to ...

ByTreefrog Therapeutics


TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies

TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies

Aiming at a first clinical trial in Parkinson’s disease in 2024, TreeFrog Therapeutics is currently expanding its pipeline of cell therapies through co-development partnerships, in the field of cardio-metabolic disorders and immuno-oncology. Already well-integrated within the Japanese ecosystem, TreeFrog Therapeutics seeks to strengthen its ties with ...

ByTreefrog Therapeutics


TreeFrog Therapeutics back in the FrenchTech120

TreeFrog Therapeutics back in the FrenchTech120

Now bringing over 70 biophysicists, stem cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the field of neurodegeneration, cardio-metabolic disorders, and immuno-oncology. In 2022, the company will open technological hubs in Boston, USA, and Kobe, Japan, ...

ByTreefrog Therapeutics


Feldan Therapeutics forms A Scientific Advisory Board and Expands Its Leadership Team

Feldan Therapeutics forms A Scientific Advisory Board and Expands Its Leadership Team

Gries has had exposure over a broad range of disease areas: oncology, inflammation and pain, the central nervous system, metabolism, cardio-renal syndrome, anti-infectives (including HIV and HCV), dermatology, ophthalmology, genito-urinary and gastroenterology. ...

ByFeldan Therapeutics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT